|
Peter Francis, M.D., Ph.D.
Oregon Health and Science University
Portland, OR
Title:
Genetic Studies Of A Nonhuman Primate Model For Age-Related Maculopathy
Non-Technical Title:
Genetics Of Macular Degeneration In Monkeys
Duration:
April 1, 2009 - March 31, 2011
|
Summary: More complete understanding of the genetic risk factors for age-related macular degeneration (AMD) is essential to the development of better treatments that are optimized for the individual. Nonhuman primates provide a uniquely useful model for AMD because they have a macula, develop age-related maculopathy, and share with humans some of the same genetic risk factors for this disease. We propose to further define genetic factors in macular disease in a large monkey colony so that these animals can be used most effectively to test new therapies and prevention strategies.
More details
Program: Macular Degeneration
Award Type: Standard
$100,000
|
|
Jonathan Haines, Ph.D.
Vanderbilt University Medical Center
Nasville, TN
Title:
Genetic examination of AMD in the Midwestern Amish
Non-Technical Title:
Genetic studies of age-related macular degeneration in Amish communities of Ohio and Indiana
Duration:
April 1, 2008 - March 31, 2011
|
Summary: By examining a population with a close community and genetic similarities, this proposal will seek to identify genetic risk factors that predispose a population to AMD.
More details
Program: Macular Degeneration
Award Type: Standard
$100,000
|
Aparna Lakkaraju, Ph.D.
Board of Regents of the University of Wisconsin System
Madison, WI
Title:
Apolipoprotein E And Cholesterol Lowering Drugs In Age-Related Macular Degeneration
Non-Technical Title:
Cholesterol homeostasis and age-related macular degeneration
Duration:
April 1, 2009 - March 31, 2012
|
Summary: The specific aims outlined in this proposal will provide a cell biological understanding of the role of a protein called apolipoprotein E and the regulation of cholesterol levels in the retinal pigment epithelial (RPE) tissue of the eye). We will also investigate the potential of two promising drugs, statins and PPARgamma agonists, which are currently being used to treat, respectively, atherosclerosis and diabetes. These drugs will be tested for their ability to maintain cholesterol balance in the RPE.
More details
Program: Macular Degeneration
Award Type: Standard
$100,000
|
|
Yun Zheng Le, Ph.D.
University of Oklahoma Health Sciences Center
Oklahoma City
Title:
Post-developmental function of the RPE-produced VEGF
Non-Technical Title:
AMD mouse model
Duration:
April 1, 2008 - May 31, 2010
|
Summary:
More details
Program: Macular Degeneration
Award Type: Standard
$100,000
|
Jinbo Liu, M.D.
Cleveland Clinic Foundation
Cleveland, OH
Title:
Identification of autoreactive T cells in AMD Patients
Non-Technical Title:
Immune mechanism underlying AMD
Duration:
April 1, 2008 - March 31, 2011
|
Summary: The experiments in this proposal will address the mechanisms underlying immune attack in the retina. This information could lead to treatment approaches not currently available.
More details
Program: Macular Degeneration
Award Type: Standard
$100,000
|
|
Gerard Lutty, Ph.D.
Johns Hopkins University
Baltimore, MD
Title:
Inflammation and oxidative stress in macular degeneration
Non-Technical Title:
Modeling immune response and oxygen radical injury due to tobacco smoke in age-related macular degeneration
Duration:
April 1, 2010 - March 31, 2012
Co-Investigator(s):
Imran Bhutto, M.D., Ph.D.
Wilmer Eye Institute
|
Summary: We will investigate the contribution of smoking to death of choriocapillaris (CC) and formation of choroidal neovascularization (CNV) in AMD. We will also evaluate the role of endogenous antioxidants in prevention of CC death and CNV in a clinically relevant animal model of AMD. Finally, using this model we will evaluate novel therapies to control the level of antioxidants (sulforaphane) and novel delivery systems for antioxidants and anti-angiogenic factors.
More details
Program: Macular Degeneration
Award Type: Standard
$100,000
|
Goldis Malek, Ph.D.
Duke University
Durham, NC
Title:
Oxidant Activated Nuclear Receptors in AMD Pathogenesis
Non-Technical Title:
Investigating the role of receptors stimulated by cigarette smoke toxins in AMD
Duration:
April 1, 2010 - March 31, 2012
|
Summary: In this proposal we are investigating the molecular pathway through which cigarette smoke oxidants stimulate retinal pigment epithelial injury (RPE) and sub-RPE deposit formation. We will use both cell cultures of RPE cells as well as mouse models to address this question.
More details
Program: Macular Degeneration
Award Type: Standard
$100,000
|
Md Nawajes Mandal, Ph.D.
University of Oklahoma Health Sciences Center
Oklahoma City, OK
Title:
Nutritional Supplement Of Phytochemical In Prevention Of AMD
Non-Technical Title:
Nutraceuticals In Prevention Of AMD
Duration:
April 1, 2009 - March 31, 2011
|
Summary: The efficacy of known potent anti-inflammatory and anti-oxidative botanical compounds such as, curcumin, sulforaphane, and caffeic acid phenethyl ester (CAPE) will be tested in animal models of retinal degeneration. The protective effect of these compounds on cell death will also be tested in cultured retina-derived cells. The mechanism of action of these compounds in retinal protection will be determined. As age-related macular degeneration (AMD) develops from oxidative-stress and chronic inflammation, we hope to find a promising compound that can be tested further in pre-clinical and clinical trials.
More details
Program: Macular Degeneration
Award Type: Standard
$100,000
|
|
Nancy Mangini, Ph.D.
The Trustees of Indiana University
Gary, IN
Title:
Role of melanin and a novel Na:Ca:K exchanger in AMD
Non-Technical Title:
Duration:
April 1, 2006 - September 28, 2010
|
Summary:
More details
Program: Macular Degeneration
Award Type: Standard
$200,000
|
Brian McKay, Ph.D.
University of Arizona
Tucson, AZ
Title:
OA1 Signaling and AMD
Non-Technical Title:
RPE Pathways Important in Supporting Retinal Survival
Duration:
April 1, 2010 - March 31, 2012
|
Summary: The studies proposed in this application investigate a molecular pathway in the retinal pigmented epithelium, RPE, that governs neurotrophic factor production. Activation of OA1 signaling is a valid and potentially import target for age-related macular degeneration (AMD) treatment. Data that support the hypothesis of this proposal will have the effect of illustrating a new and important treatment route for AMD.
More details
Program: Macular Degeneration
Award Type: Standard
$100,000
